Midnolin is a confirmed genetic risk factor for Parkinson’s disease.

Midnolin is a confirmed genetic risk factor for Parkinson’s disease.

Publication date: Oct 06, 2019

Genetic analysis of patients with familial Parkinson’s disease (PD) identified many causative genes. However, the majority of PD cases are sporadic, and the mechanisms of onset still remain unclear. Previously, we found that Midnolin (MIDN) is associated with PD in a Yamagata (Japan) cohort study and that MIDN regulates neurite outgrowth and Parkin expression in neuronal cells. In the present study, we aimed to replicate the genetic association between MIDN and PD in a large British population cohort.

In this replication study, we analyzed the copy number variations and single-nucleotide polymorphisms of the MIDN gene in a large British population on a case-control genome-wide association study dataset including 2,860 controls and 2,168 PD patients.

There was significant copy number loss in the MIDN gene with an odds ratio of 4.35 (P

Obara, Y., Sato, H., Nakayama, T., Kato, T., and Ishii, K. Midnolin is a confirmed genetic risk factor for Parkinson’s disease. 22532. 2019 Ann Clin Transl Neurol.

Concepts Keywords
Causative Military organization
Cohort Nursing research
Genetic Epidemiology
Genome Midshipman
Japan Navies
Neurite Case–control study
Odds Ratio Genetic variation
Parkinson
Risk Factor
Single Nucleotide Polymorphisms
Yamagata

Semantics

Type Source Name
gene UNIPROT LARGE1
gene UNIPROT PRKN
drug DRUGBANK Profenamine
drug DRUGBANK Trihexyphenidyl
disease MESH risk factor
gene UNIPROT MIDN

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *